SCHEMBL119413

SCHEMBL119413

COC(=O)c1cccc(S(=O)(=O)Cl)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.55
ALDH1A1 P00352 3/20 0.55
KDM4E B2RXH2 2/20 0.55
KMT2A Q03164 2/20 0.55
CA12 O43570 1/20 0.54
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
CA9 Q16790 1/20 0.54
LOX P28300 1/20 0.52
TCF4 P15884 2/20 0.51
CTNNB1 P35222 2/20 0.51
TSHR P16473 1/20 0.50
LOXL2 Q9Y4K0 1/20 0.50
SLC40A1 Q9NP59 1/20 0.50
ACLY P53396 2/20 0.49
CTSG P08311 1/20 0.49
CMA1 P23946 1/20 0.49
GAA P10253 1/20 0.49
PKM P14618 1/20 0.49
HPGD P15428 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29457845 1.00 POLB (0.55) POLBALDH1A1KDM4EKMT2ACA12
SCHEMBL2884607 0.86 LOX (0.66) POLBALDH1A1KDM4EKMT2ACA12
SCHEMBL3293304 0.84 POLB (0.57) POLBALDH1A1KDM4EKMT2ACA12
SCHEMBL1100084 0.84 ALDH1A1 (0.59) POLBALDH1A1KDM4EKMT2ACA12
SCHEMBL9008002 0.84 ALDH1A1 (0.59) POLBALDH1A1KDM4EKMT2ACA12
SCHEMBL2651155 0.84 POLB (0.61) POLBALDH1A1KDM4EKMT2ACA12
SCHEMBL15546745 0.84 ALDH1A1 (0.42) POLBALDH1A1KDM4EKMT2ACA12
SCHEMBL23380392 0.83 CA12 (0.74) POLBCA12CA1CA2CA9
SCHEMBL38455 0.83 ALDH1A1 (0.58) POLBALDH1A1KDM4EKMT2ACA12
SCHEMBL2300229 0.83 CA1 (0.70) POLBALDH1A1KDM4EKMT2ACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 536 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113905785-B Cystic fibrosis transmembrane conductance regulator 弗特克斯药品有限公司 2024-07-19 CN claimed
EP-3946595-B1 CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATING AGENTS VERTEX PHARMA (US) 2023-11-15 EP claimed
EP-3946595-A1 CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATING AGENTS Vertex Pharmaceuticals Incorporated (US) 2022-02-09 EP claimed
CN-113905785-A Cystic fibrosis transmembrane conductance regulator modulators 弗特克斯药品有限公司 2022-01-07 CN claimed
WO-2020206080-A1 CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATING AGENTS VERTEX PHARMACEUTICALS INCORPORATED (US) 2020-10-08 WO claimed
CN-108299255-B Histone deacetylase 8 selective inhibitor and preparation method and application thereof 山东大学 2020-05-19 CN claimed
EP-4225762-B1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMA (US) 2026-05-27 EP disclosed
CN-122074075-A Solid forms of modulators of cystic fibrosis transmembrane conductance regulator 弗特克斯药品有限公司 2026-05-22 CN disclosed
US-12612416-B2 Modulators of cystic fibrosis transmembrane conductance regulator VERTEX PHARMACEUTICALS INCORPORATED (US) 2026-04-28 US disclosed
EP-4650348-A1 CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR Mitsubishi Tanabe Pharma Corporation (JP) 2025-11-19 EP disclosed
US-20250340574-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMA (US) 2025-11-06 US disclosed
US-12421251-B2 Cystic fibrosis transmembrane conductance regulator modulating agents VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-09-23 US disclosed
US-12391680-B2 Compounds and compositions for the treatment of cystic fibrosis FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) 2025-08-19 US disclosed
US-5130119-A Sulfonamide or hydroxy fluorine substituted benzene for medical diagnosis SCHERING AKTIENGESELLSCHAFT (DE) 1992-07-14 US disclosed
US-4161531-A Diuretic and saluretic 5-sulfamoylbenzoic acid derivatives carrying a heterocyclic substituent HOECHST AKTIENGESELLSCHAFT (DE) 1979-07-17 US disclosed
US-4118397-A DIURETICS HOECHST AKTIENGESELLSCHAFT (DE) 1978-10-03 US disclosed
US-4111953-A DIURETICS HOECHST AKTIENGESELLSCHAFT (DE) 1978-09-05 US disclosed
US-4093735-A DIURETICS HOECHST AKTIENGESELLSCHAFT (DT) 1978-06-06 US disclosed
US-4029638-A YARNS, SULFONAMIDE GROUPS AKZONA (US) 1977-06-14 US disclosed
US-4010273-A DIURETICS, SALURETICS HOECHST AKTIENGESELLSCHAFT (DT) 1977-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12612416-B2 Modulators of cystic fibrosis transmembrane conductance regulator CFTR, CLCN2, CLIC1 POLB 3639/4885ALDH1A1 4475/4885KDM4E 4300/4885
US-20250340574-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B POLB 3310/4885ALDH1A1 3983/4885KDM4E 4306/4885
US-12391680-B2 Compounds and compositions for the treatment of cystic fibrosis CFTR, ABCB11, ABCC5 POLB 1883/4885ALDH1A1 2567/4885KDM4E 4698/4885
US-12421251-B2 Cystic fibrosis transmembrane conductance regulator modulating agents CFTR, SCNN1G, CLCN2 POLB 4205/4885ALDH1A1 2228/4885KDM4E 4085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.